Background
==========

Vitamin D is an essential fat-soluble vitamin that plays an important role in skeletal mineralization as well as regulation of secretion of hormones such as insulin, renin, fibroblast growth factor, and parathyroid hormone.[@b1-ijnrd-9-187]

In the cells, vitamin D exerts its effects through the vitamin D receptor (VDR), a nuclear transcription factor to which vitamin D binds via the carboxyl-terminal ligand-binding domain. The VDR molecule belongs to a large class of nuclear receptors that include thyroid, steroid, and retinoic acid receptors.[@b2-ijnrd-9-187],[@b3-ijnrd-9-187] The gene sequence encoding VDR can vary, resulting in polymorphic forms such as the variants produced on digestion with restriction enzymes such as *Apa*I and *Taq*I. Some of these polymorphic forms of VDR are associated with reduced effectiveness of vitamin D, which may lead to higher risk and predisposition to various bone and endocrine diseases, such as osteoporosis, rickets, urolithiasis, and diabetes mellitus type 1.[@b4-ijnrd-9-187]--[@b9-ijnrd-9-187]

The pathogenesis of idiopathic nephrotic syndrome (INS) remains inconclusive and controversial and is considered to be mediated by the immune system and the imbalance between T-helper cell subtype 1 (Th1) and Th2 cytokines, which are in turn regulated by 1,25-dihydroxy D3, which is the active form of vitamin D. Vitamin D exerts its effects through its receptor (VDR), which plays a role in the transcriptional inhibition of cytokine genes, subsequently affecting cytokine release.[@b10-ijnrd-9-187] Ethnic and genetic differences in the frequencies of the *VDR* polymorphic genotypes have been previously reported in different populations.[@b9-ijnrd-9-187],[@b11-ijnrd-9-187],[@b12-ijnrd-9-187] In this study, we explore the frequency of *VDR* gene *Taq*I and *Apa*I restriction fragment length polymorphisms (RFLPs) in Kuwaiti Arab children with INS and the effect of the different *VDR* polymorphic genotypes on steroid responsiveness.

Subjects and methods
====================

Subjects
--------

Patients below the age of 12 years with a confirmed diagnosis of INS were included in this study. These patients were referred and evaluated at a specialized pediatric nephrology clinic at Mubarak Al-Kabeer University Hospital over a period of 6 years. Diagnosis of INS was based on the presence of generalized edema, nephrotic-range proteinuria, and hypoalbuminemia with or without hyperlipidemia. Patients were categorized by their initial response to steroid treatment as steroid sensitive (SS) or steroid resistant (SR). Steroid responsiveness was defined as the disappearance of proteinuria (negative to traces in a urine dipstick test for 3 days consecutively) or a urine protein/creatinine level of \<0.2 within the first 4-week course of full-dose prednisolone therapy (60 mg/m^2^/d). Steroid resistance was defined as the persistence of proteinuria after a 4-week course of full-dose prednisolone. Steroid dependency was defined as having two consecutive relapses during steroid treatment or within 2 weeks of steroid withdrawal, while "frequent relapsers" were defined as having four or more relapses within a 12-month period. Patients with poor compliance and not on regular follow-up, as well as the infrequent-relapser patients, were excluded. All patients underwent a complete physical examination by an experienced pediatrician. A comparable number of healthy children (n=56), with the same ethnic background, were included as controls. They were evaluated by a trained pediatrician to ensure the absence of any renal disease. They were mostly selected from among patients visiting the hospital's Emergency Department for minor illnesses.

All patients and controls were analyzed for blood urea, serum creatinine, total protein, and albumin levels, as well as a complete lipid profile including serum cholesterol. Urine protein: creatinine ratio was also determined for all the study subjects. Ethical approval was obtained from the Health Sciences Center's Committee for the Protection of Human Subjects in Research as well as the Ministry of Health's Ethics Committee. Written informed consent was obtained from caregivers of both patients and controls as per guidelines of the committees.

Collection and processing of samples
------------------------------------

Approximately 5--8 mL of blood was collected from all the study subjects in appropriate tubes for subsequent laboratory analyses. Serum was isolated by centrifugation and was used for the biochemical analyses. For genotyping, the blood was collected in tubes containing the anticoagulant EDTA. Total genomic DNA was isolated from all samples by using a standard method.[@b13-ijnrd-9-187]

Genotyping of VDR--*Taq*I and --*Apa*I polymorphisms
----------------------------------------------------

The g.59979G\>T or c.1025-49G\>T (*Apa*IG→T) and g.60058T\>C or c.1056T\>C (*Taq*IT→C) polymorphic sites of the *VDR* gene (GI: 7421) were analyzed by the polymerase chain reaction (PCR)-RFLP method.[@b14-ijnrd-9-187],[@b15-ijnrd-9-187] A 740 bp fragment was amplified using the primers described earlier.[@b14-ijnrd-9-187] The PCR mixture contained 100 ng DNA template, 0.18 mM/L of each primer, 2.2 mM MgCl~2~, 0.2 mM deoxynucleotide triphosphates, and 0.8 U AmpliTaq DNA polymerase (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA). The PCR conditions used were as follows: 94°C for 5 minutes; 30 cycles consisting of 1 minute at 94°C, 1 minute at 60°C, and 90 seconds at 72°C, followed by an extension step for 10 minutes at 72°C. The PCR product was digested with 5 U *Apa*I (New England BioLabs, Boston, MA, USA) at 25°C overnight. The products of restriction enzyme cleavage were analyzed on 2% agarose gels and were visualized under UV light after staining with ethidium bromide. Alleles 'G' and 'T' were assigned based on the presence of a 740 bp (uncleaved) fragment and the 528 bp and 210 bp (cleaved) fragments, respectively ([Figure 1](#f1-ijnrd-9-187){ref-type="fig"}). The same PCR product was digested with restriction enzyme *Taq*I (New England BioLabs) at 65°C for 75 minutes to detect the *Taq*I polymorphism.[@b14-ijnrd-9-187] The products of restriction enzyme digestion were analyzed on 2% agarose gels and visualized under UV following staining with ethidium bromide. The allele 'T' was associated with the presence of a 495 bp fragment, while allele 'C' was assigned in the presence of 251 bp and 201 bp fragments ([Figure 2](#f2-ijnrd-9-187){ref-type="fig"}).[@b14-ijnrd-9-187],[@b15-ijnrd-9-187]

Statistical analysis was conducted using SPSS-IBM software version 21 (IBM Corporation, Armonk, NY, USA). The chi-square test was used to compare groups and frequencies of *VDR* genotypes, and Fisher's exact test was used for small-sized groups.

Results
=======

A total of 78 Kuwaiti children (52 males and 26 females) with a confirmed diagnosis of INS were included in this study. Their ages ranged from 13 months to 12 years, with a mean of 6.5±3.1 years. They were categorized according to steroid responsiveness into either steroid-sensitive (SS: 62 patients) or steroid-resistant (SR: 16 patients) groups. Biopsy-proven histological diagnosis of minimal-change nephrotic syndrome (MCNS) was documented in 32 patients in the SS group for steroid dependency. Focal segmental glomerulosclerosis (FSGS) was histologically proven in 13 of the 16 patients with steroid resistance. Of the other three SR patients, MCNS was found in two and membranous glomerulonephritis in one patient. Hypertension was noted in nine patients at diagnosis and in additional seven patients after initiation of prednisolone treatment. None of the steroid responders developed steroid resistance during the course of the disease, whereas five of the SR patients showed partial remission later on during the course of the disease. Only three patients of the FSGS group developed end-stage renal disease during the study period and three patients had chronic kidney disease at the end of the study. All 78 patients received prednisolone as a first-line therapy, while 58 patients required a second-line therapy with either cyclophosphamide (n=42) or calcineurin inhibitors (n=28), in addition to methylprednisolone pulse therapy when indicated. Patients were followed up for a mean period of 39 months (range: 6--72 months). [Table 1](#t1-ijnrd-9-187){ref-type="table"} summarizes the demographic and laboratory data on INS patients compared to the controls.

The results of *VDR* genotyping in terms of *Taq*I polymorphism are presented in [Table 2](#t2-ijnrd-9-187){ref-type="table"}. The TT genotype was detected in 41% of the INS patients compared to 42% of the controls (*P*=0.816). The heterozygous TC genotype was detected in 33% of INS patients compared to 46% of the controls (*P*=0.462). The CC genotype was detected in 25.6% of INS patients and 21% of the controls (*P*=0.719). The C-allele frequency, in its homozygous and heterozygous forms, was 71% in INS patients compared to 63% in the controls (*P*=0.342).

No significant difference was detected for all the three genotypes in terms of the *VDR*--*Apa*I polymorphism in INS patients compared to the controls (*P*=0.76, *P*=0.207, and *P*=0.364, respectively, for GG, GT, and TT genotypes). The T-allele frequency, in its homozygous and heterozygous forms, was 90% in INS patients compared to 93% in the controls (*P*=0.076; [Table 2](#t2-ijnrd-9-187){ref-type="table"}).

When the INS patients were subdivided according to steroid responsiveness, no significant statistical difference was found in allele frequencies between the SS and SR subgroups when compared with each other, nor when compared to controls.

Discussion
==========

VDR is a member of the steroid/thyroid hormone receptor family through which the action of the active form of vitamin D is mediated.[@b16-ijnrd-9-187],[@b17-ijnrd-9-187] VDR binds to the active form of intracellular vitamin D (calcitriol or 1,25-dihydroxy D3) to form a molecule that interacts with the nuclei of the target cells to produce various biological effects, such as immunity, growth, bone mineralization, and differentiation of many cells, as well as playing different functions in different body organs, such as muscles/vessels.[@b2-ijnrd-9-187],[@b18-ijnrd-9-187] The *VDR* gene maps to the locus 12q12-q14 and comprises eleven exons that span \~75 kb. The 5′ noncoding end of the gene includes regions of exons 1A, 1B, and 1C.[@b1-ijnrd-9-187] The translated gene product (protein) is encoded by exons 2--9. Exons 7--9 play a critical role in binding to vitamin D. Allelic variations in *VDR* are involved in their function, suggesting in turn that allelic variations in *VDR* cause functional differences in the potency of 1,25-dihydroxy D3 as an immunosuppressive hormone.[@b19-ijnrd-9-187] *VDR* gene polymorphism (including *Taq*I and *Apa*I genotypes) is known to be genetically determined and affected by ethnicity. Our study is considered novel as it is the first of its kind reporting this polymorphism in INS Arab patients from the Middle East region. Many previous studies on the effect of *VDR* gene polymorphism on renal diseases showed conflicting results.[@b9-ijnrd-9-187],[@b11-ijnrd-9-187],[@b12-ijnrd-9-187] No effects of the different *VDR* polymorphic genotypes on both chronic kidney disease and end-stage renal disease were previously documented,[@b20-ijnrd-9-187]--[@b25-ijnrd-9-187] whereas studies on systemic lupus erythematosus nephritis, including secondary nephrotic syndrome with or without renal dysfunction, reported an association of renal involvement with the bb genotype of *Bsm*I polymorphism, which is a common single-nucleotide polymorphism of the *VDR* gene.[@b19-ijnrd-9-187] INS has been widely considered to be a primary immune disease associated with immune regulatory imbalance between Th1 and Th2 cytokines, which are thought to play major roles in the pathogenesis and progression of the disease.[@b10-ijnrd-9-187],[@b26-ijnrd-9-187]--[@b28-ijnrd-9-187] On the other hand, the important role of *VDR* gene polymorphism in INS could be mediated through its direct effect on the function and potency of 1,25-dihydroxy D3, which is considered an immune suppressor hormone that negatively regulates the production of different cytokines and downregulation of the immune system.[@b19-ijnrd-9-187] Reports on *VDR* gene polymorphism in children with INS are scarce. The only report we could find was by Jafar et al [@b29-ijnrd-9-187] who reported significant difference in the frequency of *Apa*I polymorphic genotype in INS Indian patients of East Asian origin. In the same study, no difference was reported in the *Taq*I genotype frequency in the same patients compared to controls. In our patients, we found no association of the two polymorphic genotypes with INS. The fact that the ethnic and genetic background of the Arab race differs from that of the East Asian population might easily explain the difference in the results of the two studies. Moreover, we did not have any previous data about the common *VDR* polymorphic genotypes in our general population, which might not be reflected by the relatively small number of controls we used. The other unique aspect of our study was exploring the association of *VDR* polymorphism (*Taq*I and *Apa*l) with the clinical pattern of INS in terms of steroid responsiveness, which has not been previously reported. We could not elicit any differences in *VDR* genotype frequency patterns in both SS and SR groups. This was an unexpected finding knowing the immune-modulating and suppressive effect of vitamin D3, which is expected to be synergistic to steroid effects in INS.

Conclusion
==========

Our data do not support *VDR* gene polymorphisms (*Apa*I and *Taq*I) as being genetic determinants of susceptibility to INS. No association between *VDR* gene polymorphisms and steroid responsive could be elicited.
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![Determination of genotypes for *VDR*--*Apa*I polymorphism by using PCR-RFLP method.\
**Notes:** Lane 1, *M~r~* size markers; lane 2, uncleaved PCR product (740 bp); lanes 3--5, *Apa*I cleavage pattern of PCR samples from subjects with TT genotype; lane 6, *Apa*I-cleaved PCR products from a subject with GT genotype; lane 7, *Apa*I-cleaved PCR product from a subject with GG genotype. The products were analyzed on 2% agarose gels and visualized under UV light after staining with ethidium bromide.\
**Abbreviations:** PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; VDR, vitamin D receptor.](ijnrd-9-187Fig1){#f1-ijnrd-9-187}

![Determination of genotypes for *VDR*--*Taq*I polymorphism by using PCR-RFLP method.\
**Notes:** Lanes 1, 5, and 8 show *Taq*I cleavage pattern of samples from subjects with TT genotype; lanes 2--4 and 7 show the *Taq*I-cleaved PCR product from subjects with TC genotype; lane 6 shows the *Taq*I-cleaved PCR products obtained from a subject with CC genotype. The products were analyzed on 2% agarose gels and visualized under UV light after staining with ethidium bromide.](ijnrd-9-187Fig2){#f2-ijnrd-9-187}

###### 

Clinical and laboratory data of controls and patients with INS

                                   INS patients (n=78)   *P*-value   Controls (n=56)   Normal range   
  -------------------------------- --------------------- ----------- ----------------- -------------- ------------
  Mean age, years                  5.2±4.1               9.4±1.5     \<0.0002          7.8±2.3        
  Sex                                                                                                 
   Male                            39                    13                            30             
   Female                          23                    3                             26             
  Mean serum creatinine, µmol/L    53±19                 91±18       \<0.0001          58±10          (15--88)
  Mean blood urea, mmol/L          5.6±2.1               8.2±3.4     \<0.0001          4.2±3.1        (2.5--6.0)
  Mean serum protein, g/L          59±3                  24±4        \<0.0001          67±3           (68--80)
  Mean serum albumin, g/L          29±5                  18±7        \<0.0001          37±7           (35--45)
  Mean serum cholesterol, mmol/L   5.8±0.6               6.9±1.3     \<0.0002          3.3±0.36       (3.1--5.2)
  Mean UP:Cr ratio, mg/mg          3.3±0.6               5.6±1.4     \<0.0001          0±0.09         (≤ 0.2)

**Notes:** Data presented as mean ± standard deviation. *P*-values are significant if ≤0.05.

**Abbreviations:** INS, idiopathic nephrotic syndrome; SR, steroid resistant; SS, steroid sensitive; UP:Cr, urinary protein:creatinine ratio.

###### 

Incidence of *VDR* gene *Taq*I and *Apa*I polymorphism genotypes in children with INS and controls

  Genotype/alleles                      INS (%)     Controls (%)   *P*-value[\*](#tfn3-ijnrd-9-187){ref-type="table-fn"}
  ------------------------------------- ----------- -------------- -------------------------------------------------------
  *Taq*I genotype                                                  
  TT                                    32 (41.5)   21 (42)        0.816
  TC                                    26 (33.3)   23 (46)        0.462
  CC                                    20 (25.6)   12 (21.4)      0.719
  Subjects with at least one C-allele   56 (71.4)   35 (63)        0.342
  *Apa*I genotype                                                  
  GG                                    8 (10.3)    4 (7.2)        0.760
  GT                                    32 (41.0)   30 (54.5)      0.207
  TT                                    38 (48.7)   22 (39.3)      0.364
  Subjects with at least one T-allele   70 (89.7)   52 (92.8)      0.760

**Note:**

*P*-values are significant if ≤0.05.

**Abbreviations:** INS, idiopathic nephrotic syndrome; *VDR*, vitamin D receptor.
